ReviewCancers2022
Primary Effusion Lymphoma: A Clinicopathologic Perspective.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Fluid overload-associated large B-cell lymphoma: two case report and review of literature.Frontiers in oncology · 2025Pooled it
- Human Herpesvirus 8 Causes a Wide Spectrum of Disease in Liver Transplant Recipients and May be Donor Derived: Case Series and Systematic Review of an Emerging Challenge.Transplant infectious disease : an official journal of the Transplantation SocietyPooled it
- Extracavitary Primary Effusion Lymphoma: Diagnostic Challenges and Differential Diagnosis in a Resource-Constrained South African Setting.International journal of surgical pathology · 2026Article
- Familial lymphoma and genetic predisposition: an updated review.BMC medical genomics · 2026Review
- Case Report: Synchronous Manifestations of Kaposi Sarcoma Herpesvirus-Associated Disorders.Cancer reports (Hoboken, N.J.) · 2026Article
- Multi-cavity Primary Effusion Lymphoma in a Cirrhotic Patient: A Rare Cause of Chylous Effusion.Cureus · 2026Article
- Fluid Overload-Associated Large B-Cell Lymphoma Presenting as Isolated Pleural Effusion.Hematology reports · 2026Article
- Imaging of peritoneal surface malignancies: diagnosis and clinical implications.Abdominal radiology (New York) · 2026Review
- Bibliometric review of primary effusion lymphoma research: Current status, hotspots, and future prospects.Transplantation · 2026Review
- Article
- Intrathoracic manifestations of hematologic malignancies: a narrative review.Annals of translational medicine · 2025Review
- Human Herpes Virus-8 Oral Shedding Heterogeneity Is Due to Varying Rates of Reactivation from Latency and Immune Containment.Viruses · 2025Article
- Heterogeneous Activation of Signaling Pathways and Therapeutic Vulnerabilities in KSHV-Associated Primary Effusion Lymphoma Cell Lines.Journal of medical virology · 2025Article
- Current State of AIDS-Related Malignant Lymphoma.Viruses · 2025Review
- Review
- Primary Pleural Lymphoma in an Immune-Competent Patient: A Diagnostic and Therapeutic Challenge.Journal of personalized medicine · 2025Article
- An Unusual Case of Extracavitary/Solid Variant Primary Effusion Lymphoma With Associated Hemophagocytic Lymphohistiocytosis.Journal of medical cases · 2025Article
- Impact of NF-κB Signaling and Sirtuin-1 Protein for Targeted Inflammatory Intervention.Current pharmaceutical biotechnology · 2025Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary effusion lymphoma (PEL) is a rare, aggressive B-cell lymphoma that usually localizes to serous body cavities to subsequently form effusions in the absence of a discrete mass. Although some tumors can develop in extracavitary locations, the areas most often affected include the peritoneum, pleural space, and the pericardium. PEL is associated with the presence of human herpesvirus 8 (HHV8), also called the Kaposi sarcoma-associated herpesvirus (KSHV), with some variability in transformation potential suggested by frequent coinfection with the Epstein-Barr virus (EBV) (~80%), although the nature of the oncogenesis is unclear. Most patients suffering with this disease are to some degree immunocompromised (e.g., Human immunodeficiency virus (HIV) infection or post-solid organ transplantation) and, even with aggressive treatment, prognosis remains poor. There is no definitive guideline for the treatment of PEL, although CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine, and prednisone) are frequently prescribed and, given the rarity of this disease, therapeutic focus is being redirected to personalized and targeted approaches in the experimental realm. Current clinical trials include the combination of lenalidomide and rituximab into the EPOCH regimen and the treatment of individuals with relapsed/refractory EBV-associated disease with tabelecleucel.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.